What is Eucalyptus?
Eucalyptus is an Australian digital health company founded in 2019 and headquartered in New South Wales. It operates within Australia's two-payer healthcare system, offering a private-pay option directly to consumers. The company aims to provide accessible and convenient healthcare solutions, differentiating itself by focusing on direct consumer engagement rather than solely relying on government or traditional insurance models. Its business model is designed to complement existing healthcare structures by offering a streamlined, user-centric approach to private medical services.
How much funding has Eucalyptus raised?
Eucalyptus has raised a total of $112.3M across 3 funding rounds:
Series A
$30M
Series B
$22.3M
Series C
$60M
Series A (2021): $30M with participation from Blackbird
Series B (2021): $22.3M led by W23, NewView Capital, AirTree Ventures, and Blackbird Ventures
Series C (2022): $60M supported by BOND
Key Investors in Eucalyptus
Blackbird
Blackbird is an Australian venture capital firm that exists to supercharge the company's most ambitious founders. Blackbird partners with founders at the very beginning and surrounds them with other founders who have built successful technology companies before.
NewView Capital
NewView Capital is a venture growth firm that specializes in investing in high-potential enterprise software and fintech companies through primary and secondary investments. The firm provides flexible capital tailored to the needs of its partners, along with operational guidance to help companies navigate critical growth decisions.
AirTree Ventures
Airtree is an early-stage venture capital firm that supports Australian and New Zealand founders in building iconic technology companies. The firm has a portfolio of over 125 companies and provides various programs to foster collaboration among emerging founders, operators, and investors.
What's next for Eucalyptus?
The recent major strategic investment in Eucalyptus signals a strong confidence from its backers in the company's expansion strategy. This capital infusion is expected to fuel further development of its platform, enhance customer acquisition efforts, and potentially broaden its service offerings across Australia. Eucalyptus is poised to leverage this financing to solidify its position as a key player in the direct-to-consumer healthcare market, adapting to evolving patient needs and technological advancements within the industry.
See full Eucalyptus company page
